Total labs
30
Total footprint
30,000 sq ft
Set to open in 2026, OMX will offer the much-needed lab space in Bristol that scaling Deep Tech companies often struggle to find — and it will do so within the supportive, well-connected ecosystem built by Science Creates.
Join our community of scientific entrepreneurs developing technologies that include groundbreaking cancer treatments, enhanced battery technologies and seaweed-based biomaterials.
Located in the heart of Bristol and connected to our Old Market incubator, OMX is designed with the specialised services and features that Deep Tech R&D demands, plus the flexibility that growing ventures need.
With 30,000 sq ft of lab, office and meeting space, OMX offers a range of options depending on the size of your company — from lab-only options to renting full suites including two labs and a private office.
Membership includes access to our platform of support, providing opportunities to attend workshops and events, connect with other founders, and find a mentor.





Discover the lab space that's available to rent in our newest Bristol incubator and discuss your scaling startup needs with our team today.



Travel between locations is measured in walking distance
St Philips Rd & Midland Rd
0.5 miles / 11 min
0.7 miles / 15 min

GenomeKey is transforming how healthcare clinicians diagnose and treat infections like sepsis to improve patient outcomes. Using cutting-edge machine learning and DNA sequencing, the company is developing a next-generation diagnostic device to identify bacterial genomes and determine their antimicrobial susceptibility directly from patient blood in just a few hours, rather than days. This enables clinicians to prescribe the right antibiotics for patients with much more efficiency and accuracy, reducing costs, minimising unnecessary antibiotic use and ultimately saving millions of lives from the world’s leading cause of death.

Kelpi is tackling plastic pollution by developing sustainable alternatives to single-use plastic packaging. It uses seaweed to create a unique bioplastic coating that provides a world-leading water barrier for new-generation packaging while being recyclable, biodegradable, and low carbon. By working with major food and drink, cosmetics and home care brands, Kelpi is already reducing reliance on fossil-fuel plastics and paving the way for a greener future in these industries.

Reach Industries is optimising lab and scientist efficiency with its Lumi™ visual intelligence platform. By automating data capture and analysis for experiments, observations and complex scientific workflows, the platform functions as a streamlined operating system that is accelerating R&D, improving compliance and increasing reproducibility.




Argonaute RNA is developing safe, reliable and targeted methods of temporarily silencing genes in different tissue cells. It does this via the proprietary modification of small interfering RNA (siRNA), using a novel stabilisation method to overcome previous obstacles to developing siRNA drugs for healthcare.

Anaphite is decarbonising battery production by accelerating the electric vehicle (EV) industry’s shift to dry battery electrode coating. Its technology platform solves the challenges of dry mixing and manufactures film-forming dry powders called Dry Coating Precursor (DCP®). This process enables cell manufacturers to reduce their energy use by up to 30% and create better, more sustainable batteries at lower cost.

Lifecare is committed to improving the lives of people and pets with diabetes. It is developing the next-generation of miniaturized and implantable nanobiosensors for correct and continuous monitoring of glucose and other biomarkers to the market. The company’s spin-off entity Lifecare Chemistry Ltd was founded to enhance research collaboration and secure ownership of its improved analyte-specific chemical receptor developments.




GenomeKey is transforming how healthcare clinicians diagnose and treat infections like sepsis to improve patient outcomes. Using cutting-edge machine learning and DNA sequencing, the company is developing a next-generation diagnostic device to identify bacterial genomes and determine their antimicrobial susceptibility directly from patient blood in just a few hours, rather than days. This enables clinicians to prescribe the right antibiotics for patients with much more efficiency and accuracy, reducing costs, minimising unnecessary antibiotic use and ultimately saving millions of lives from the world’s leading cause of death.

Extracellular is developing cell culture technologies to use the cell samples of living animals and plants to create sustainable alternatives to commercial products in the cosmetic, material and food industries. As a bioprocessing and manufacturing partner, it provides solutions from cell-line and scale-up development to facilitating routes to market, supporting other biotech companies seeking to develop greener consumer products such as cultivated meat, dairy products, leather, cotton and active ingredients for cosmetics.

CoED Biosciences is transforming human tissue separation for adoptive cell therapy and research purposes. Its Column of Expansion and Differentiation (CoED) device harnesses the power of chemotaxis and gravity to gently purify and extract immune cells from blood or tumour biopsies. The process preserves both the integrity and functionality of the tissues without the need for magnets or centrifugation, saving valuable time and resources.


